A NEW ANTIBIOTIC, MEDERMYCIN Sir:
Medermycin, an antibiotic active against gram-positive bacteria including staphylococci resistant to several antibiotics was obtained from cultured broths of a Streptomyces K73 recently isolated from a soil sample collected in Tokyo.
Streptomyces K73 is a chromogenic organism similar to Streptomyces antibioticus, S. bikiniensis and S. tanashiensis. Intensive taxonomical studies indicated a particular resemblance with S. tanashiensis IFO 12919, a strain that produces the antibiotic luteomycin1). Although there are some different cultural features, we have designated K73 as a strain of S. tanashiensis2).
For the production of medermycin, K73 was cultured at 28°C with aeration and agitation in the following medium : starch 3.0%, peptone 0.5 %, meat extract 0.5 dry yeast 0.3 % and NaCl 1.0 %. The potency of medermycin, assayed by the use of a sensitive strain, Staphylococcus aureus FDA 209P, reached a maximum value at approximately 38 hours. The cultured broth was filtered at pH 2.0 by the aid of Celite 545 and the dark brown broth filtrate adjusted to pH 4.0 was passed through a column of non-ionic resin, Amberlite XAD II. Medermycin was adsorbed to the resin and eluted with 70 % aqueous acetone. The active eluate fraction was evaporated in vacuo and the aqueous residue was extracted at pH 2.0 with a half volume of chloroform to remove a part of dark pigment. The aqueous fraction was adjusted to pH 7.5 and extracted repeatedly with a half volume of ethyl acetate. Medermycin in the ethyl acetate extract was then transferred into an aqueous solution by extraction with a small volume of dil.HCl and this solution was lyophilized after adjusting the pH 5.5. To prepare pure medermycin, the lyophilized preparation was chromatographed on phosphonomethyl cellulose (PPM cellulose). A small amount of crude preparation was applied to a column of PPM cellulose buffered at pH 4.0 with 0.02M acetate buffer, and the column was developed with the same buffer.
When the buffer was changed to pH 5.0, a minor component was eluted. Medermycin, the major component was eluted by 0.02M phosphate buffer pH 6.0. Medermycin was collected and the above ethyl acetate extraction procedure was repeated through the liophilization step to produce an orange-colored product.
Medermycin was recrystallized two or more times from n-butanol. Chemical, physicochemical and biological characterization of medermycin were performed on this preparation.
Medermycin is a mono-basic substance of pKa 9.5. Its stable orange crystals were isolated as a monohydrochloride of m.p. 180°C (decomp.) and of [a]22 170° (c 1, methanol).
The mono-hydrochloride is soluble in water and lower alcohols, slightly soluble in benzene, chloroform, ethylacetate and ethyl ether, but insoluble in hexane, cyclohexane and petroleum ether. It gives a color reaction characteristic of quinone groups Acidic to neutral pH range aqueous solutions of this antibiotic are orange-colored, but alkaline solutions are dark violet. Medermycin can be regarded as an indicator type antibiotic. Although medermycin base was too unstable for mass spectrographic analysis, the molecular weight and molecular formula was derived from studies with the mono-and diacetyl derivatives.
Mono-acetyl medermycin signaled at 2.12 ppm in NMR spectrum. It has a parent peak at m/e 501 in the mass spectrum. A molecular formula of C26H31NO9 is proposed for this mono-acetyl derivative.
Analysis: Calcd. for C26H31NO9. (Fig. 1) . The IR spectrum of medermycin is illustrated in Fig. 2 Xanthomonas oryzae and Shigella fiexneri were inhibited at concentrations of 6 and 12 mcg/ ml respectively, but the other eleven gram-negative bacteria required 50 mcg/ml or more.
Antitumor activity of medermycin was evaluated by the effect against YOSHIDA sarcoma cells intraperitoneally transplanted into rats 72 hours before administration of the antibiotic.
No prolongation in survival times was observed for treated rats as compared with those of controls, at medermycin dosages of 0.5-1.5 mg/kg/day for 5 days.
Another test for antitumor activity was carried out by the method of SATO.3) One dose of medermycin was injected intraperitoneally and subsequently sarcoma cells were removed every day puncture, stained and observed. By this test procedure, a weak antitumor activity was recognized only at 24 hours in rats dosed at 1.0 and 5.0 mg/kg. Acute LD50 toxicities of medermycin in mice by intravenous, intraperitoneal and oral administrations were 8.8, 7.8 and 620 mg/kg respectively.
Medermycin is in many respects somewhat similar to quinoid antibiotics kinamycins A and 0,I), but it is most closely related to luteomycin6,7) and antitumor substance No. 2898,9 
